These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 14655507)

  • 1. [Aldosterone blocking -- a rediscovered therapy principle].
    MMW Fortschr Med; 2003 Oct; 145(44):43. PubMed ID: 14655507
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R; McMurray JJ
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade.
    Del Vecchio L; Procaccio M; Viganò S; Cusi D
    Nat Clin Pract Nephrol; 2007 Jan; 3(1):42-9. PubMed ID: 17183261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone blockade in patients with heart failure and a reduced left ventricular ejection fraction.
    Pitt B
    Eur Heart J; 2009 Feb; 30(4):387-8. PubMed ID: 19190013
    [No Abstract]   [Full Text] [Related]  

  • 7. Aldosterone and cardiovascular disease: smoke and fire.
    Calhoun DA
    Circulation; 2006 Dec; 114(24):2572-4. PubMed ID: 17159070
    [No Abstract]   [Full Text] [Related]  

  • 8. Aldosterone receptor blockade in patients with left ventricular systolic dysfunction following acute myocardial infarction.
    Brandimarte F; Blair JE; Manuchehry A; Fedele F; Gheorghiade M
    Cardiol Clin; 2008 Feb; 26(1):91-105, vii. PubMed ID: 18312909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic therapies across the continuum of left ventricular dysfunction.
    Abraham WT; Greenberg BH; Yancy CW
    Am J Cardiol; 2008 Sep; 102(5A):21G-28G. PubMed ID: 18722188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study.
    Izawa H; Murohara T; Nagata K; Isobe S; Asano H; Amano T; Ichihara S; Kato T; Ohshima S; Murase Y; Iino S; Obata K; Noda A; Okumura K; Yokota M
    Circulation; 2005 Nov; 112(19):2940-5. PubMed ID: 16275882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone antagonism in chronic kidney disease.
    Ponda MP; Hostetter TH
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):668-77. PubMed ID: 17699271
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction.
    Greenberg B; Zannad F; Pitt B
    Am J Cardiol; 2006 May; 97(10A):34F-40F. PubMed ID: 16698333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction].
    Ruta J; Ptaszyński P; Maciejewski M; Chizyński K; Goch JH
    Przegl Lek; 2006; 63(12):1249-51. PubMed ID: 17642132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uncertainty on the use of aldosterone antagonists for primary therapy for sudden cardiac death in the setting of implanted devices.
    Kloner RA; Cannom DS
    Circulation; 2007 Jun; 115(23):2983-9; discussion 2989. PubMed ID: 17562969
    [No Abstract]   [Full Text] [Related]  

  • 15. Aldosterone blockade in patients with acute myocardial infarction.
    Solomon HA
    Circulation; 2003 Dec; 108(25):E173; author reply E173. PubMed ID: 14691030
    [No Abstract]   [Full Text] [Related]  

  • 16. Aldosterone receptor antagonism in heart failure.
    Jennings DL; Kalus JS; O'Dell KM
    Pharmacotherapy; 2005 Aug; 25(8):1126-33. PubMed ID: 16207104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of heart failure following myocardial infarction.
    Struthers AD
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii14-6; discussion ii31, ii43-8. PubMed ID: 15831601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A symposium: International update--the important role of aldosterone and aldosterone antagonism in cardiovascular medicine. Based on symposia held in Brussels, Belgium and Newport Beach, California.
    Am J Cardiol; 1990 Jun; 65(23):1K-57K. PubMed ID: 2353664
    [No Abstract]   [Full Text] [Related]  

  • 19. Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?
    Coca SG; Perazella MA
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):497-512. PubMed ID: 15889977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Profibrotic effects of aldosterone].
    Van Den Meiracker AH; Huizenga AT; Boomsma F
    Ned Tijdschr Geneeskd; 2004 Jul; 148(31):1532-6. PubMed ID: 15366722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.